% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

  • stupid_hobo73 stupid_hobo73 Jun 18, 2013 1:16 PM Flag

    Wall St. is so corrupt

    shouldn't a stock go down AFTER a major brokerage firm slashes it's price target on a stock by 16%? Merrill Lynch front-runs it's own research....either for their prop desk of select clients....what a joke....stock tanks for days leading up to the "secret" downgrade....then pops over a buck on the actual announcement.....I can't believe none of these guys ever go to is stealing.....does not effect the long term shareholders a bit....but pathetic nonetheless....bunch of crooks.....

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • afriendofthedevilsafriendofmine afriendofthedevilsafriendofmine Jun 18, 2013 6:01 PM Flag

      perhaps it was this out today for StreetInsider (by way of Seeking Alpha):

      Leerink Swann today maintained an Outperform rating on Genomic Health Inc. (NASDAQ: GHDX) with a price target of $41.00. Analyst Dan Leonard noted early signs of prostate test adoption.

      "We came away marginally more encouraged on early adoption of GHDX's prostate cancer test following recent conversations with two MEDACorp urologists. While many clinical questions remain, we continue to see some upside to our prostate test volume expectations for GHDX," said Leonard. "While the two urologists generally had mixed views of the test's utility (one was more positive than the other), both had already ordered the test for some of their patients."

      "Our conversations further reinforced our view that there is appetite in the urology community to augment the current clinical decision process when determining which patients are candidates for active surveillance vs. otherwise," added the analyst.

29.97+0.06(+0.20%)Oct 27 4:00 PMEDT